Pilot Study of a Novel Type of CT Scan to Assess Treatment Response During Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer
Conditions
Non-small Cell Lung Cancer Stage III
Conditions: official terms
Carcinoma, Non-Small-Cell Lung - Lung Neoplasms
Study Type
Observational
Study Phase
N/A
Study Design
Observational Model: Cohort, Time Perspective: Prospective
Overall Status
Recruiting
Summary
Dual-energy CT (DECT) provides information on the blood volume in tumors and lymph nodes. As tumors respond to treatment, preliminary data suggests that the blood volumes changes as well. Investigators are therefore using DECT to test whether it can be used on radiation treatment to rapidly assess response to treatment.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Patients aged greater than 18 years with a diagnosis of stage III non-small cell lung cancer.

- Planned treatment with either definitive chemoradiotherapy or preoperative chemoradiotherapy followed by surgical resection.

- PET-CT study within 4 weeks of next available DECT study.

- Patients must have measurable primary and nodal disease, defined by at least one lesion (primary and lymph node) greater than 1 cm.

- Kidney function sufficient to tolerate iodine-based CT contrast.

- No allergy to iodine-based contrast.

- Ability to understand and the willingness to sign informed consent.

Exclusion Criteria:

- Participants with a prior history of thoracic radiotherapy.

- Participants may not be receiving any other study agents.

- Inability to tolerate CT contrast

- Pregnant women are excluded from this study because radiotherapy has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with radiotherapy, breastfeeding should be discontinued if the mother is treated with radiotherapy. These potential risks may also apply to other agents used in this study.
Location
Rush University Medical Center
Chicago, Illinois, United States
Status: Recruiting
Contact: David J Sher, MD, MPH - 312-942-6817 - david_sher@rush.edu
Start Date
January 2014
Completion Date
March 2015
Sponsors
Rush University Medical Center
Source
Rush University Medical Center
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page